Press Releases

30.09.2021
DGAP-Media

Aladdin Healthcare Technologies SE announces Delay in the publication of 2021 Half Year Financial Statements

BERLIN/LONDON September 30, 2021 - Aladdin Healthcare Technologies SE (“Aladdin”, ISIN: DE000A12ULL2), a leading developer of Artificial Intelligence (AI) based healthcare diagnostics and drug discovery applications, announces that, due to delays in the audit of Aladdin Healthcare Technologies SE and additional time being required by the Company to finalise the 2020 annual financial statements, the Company is not in a position to meet the deadline for the publication of its audited annual financial statements for the Half Year ended 30 June 2021.

The deadline falls due Thursday, 30 September 2021. The company had been focused on preparing and finalising financial statements for the year ended 31 December 2020, which it has now published. Therefore, the entire process of the preparation of the financial statements for the half year ended 30 June 2021 has been delayed.

The Company will be using its best endeavours to ensure that the financial statements for the half year ended 30 June 2021 will be completed by the 31 October 2021.

About Aladdin Healthcare Technologies SE

Aladdin Healthcare Technologies SE (and its wholly owned subsidiary Aladdin Healthcare Technologies Ltd.) is a leading developer of AI healthcare diagnostics and drug discovery applications that can accelerate both early stage disease diagnosis and the end-to-end drug discovery process. Aladdin targets aged related disease including a significant focus on Alzheimer’s disease. Aladdin accomplishes this by collaborating with numerous partners within the global healthcare ecosystem to confidentially and securely gather targeted data including, genome, tabular, MRI, PET, cognition and other lifestyle data. These datasets are then analysed by our award-winning AI team and used to develop proprietary AI tools that can assist healthcare professionals to more accurately and efficiently diagnose aged related diseases. This new diagnostic process will save significant time and costs for healthcare professionals. Additionally, our AI drug discovery platform will be used to by pharmaceutical Companies to speed up drug development, clinical trials and predict outcomes more accurately.

Website Link: www.aladdinid.com
GSIN: A12ULL
ISIN: DE000A12ULL2
TICKER SYMBOL: NMI

For further information
Aladdin Healthcare Technologies Ltd.
24-26 Baltic Street West
London EC1Y 0UR
Phone +44 7714 719696
Email: info@aladdinid.com

Contact Press
CROSS ALLIANCE communication GmbH
Susan Hoffmeister
Phone +49 89 1250 90330
Email: sh@crossalliance.de
www.crossalliance.de